MultiCell Technologies, Inc. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 34

MultiCell Technologies, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “MultiCell Technologies, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- MultiCell Technologies, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MultiCell Technologies, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MultiCell Technologies, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MultiCell Technologies, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate MultiCell Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MultiCell Technologies, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MultiCell Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MultiCell Technologies, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MultiCell Technologies, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
MultiCell Technologies, Inc. Snapshot
MultiCell Technologies, Inc. Overview
Key Information
Key Facts
MultiCell Technologies, Inc. – Research and Development Overview
Key Therapeutic Areas
MultiCell Technologies, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
MultiCell Technologies, Inc. – Pipeline Products Glance
MultiCell Technologies, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
MultiCell Technologies, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
MultiCell Technologies, Inc. – Drug Profiles
MCT-125
Product Description
Mechanism of Action
R&D Progress
MCT-175
Product Description
Mechanism of Action
R&D Progress
MCT-465
Product Description
Mechanism of Action
R&D Progress
MultiCell Technologies, Inc. – Pipeline Analysis
MultiCell Technologies, Inc. – Pipeline Products by Therapeutic Class
MultiCell Technologies, Inc. Pipeline Products By Target
MultiCell Technologies, Inc. – Pipeline Products by Route of Administration
MultiCell Technologies, Inc. – Pipeline Products by Molecule Type
MultiCell Technologies, Inc. - Dormant Projects
MultiCell Technologies, Inc. – Company Statement
MultiCell Technologies, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
Jun 14, 2010: MultiCell Retains CDSS To Manage MCT-125 Phase IIb Clinical Trial For PMSF In UK
Feb 06, 2007: MultiCell Technologies Announces Progress For MCT-125's Anticipated Phase IIb Clinical Trial
Dec 15, 2006: MultiCell Technologies Fulfills Upfront License Fee Payment Obligation To Amarin Neuroscience For MCT-125
Financial Deals Landscape
MultiCell Technologies, Inc., Deals Volume Summary, 2004 to YTD 2010
MultiCell Technologies, Inc., Deals Summary By Region, 2004 to YTD 2010
MultiCell Technologies, Inc., Deals Summary, 2004 to YTD 2010
MultiCell Technologies, Inc. Detailed Deal Summary
Debt Offering
MultiCell Immunotherapeutics Completes Private Placement Of Convertible Debentures For $2 Million
MultiCell Technologies Completes Private Placement Of Convertible Debentures For $0.1 Million
MultiCell Technologies Enters Into Co-Development Agreement With Maxim Biotech
Licensing Agreements
MultiCell Technologies Enters Into Licensing Agreement With Corning
MultiCell Technologies Enters Into Licensing Agreement With Eisai
MultiCell Technologies Enters Into Licensing Agreement With Amarin Neuroscience
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• The UK Education Industry Forecast to 2015 - Dominance of Higher Education Sector
• eLEARNING - Global Strategic Business Report
• The United Kingdom Defense Industry - Competitive Landscape and Strategic Insights to 2017: Market Profile
• UK Civil Security Market - Revenue Opportunities and Stakeholder
• The United Kingdom Defense Industry - Market Attractiveness and Emerging Opportunities to 2017: Market Profile
• UK Manned Security Services Market Development Report
• Military Aircraft Market in the United Kingdom to 2021: Market Brief
• Future of the UK Defense Industry - Market Attractiveness, Competitive Landscape and Forecasts to 2017
• Further & Higher Education Market Report 2013
• Aerospace and Defense Industry - Global Strategic Business Report